Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,960.00
Bid: 1,969.00
Ask: 1,971.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.102%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,960.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

19 Apr 2016 12:57

RNS Number : 6687V
Hikma Pharmaceuticals Plc
19 April 2016
 

Annex DTR3

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons

All relevant boxes should be completed in block capital letters

1.

Name of the Issuer:

 

Hikma Pharmaceuticals PLC

2.

State whether the notification relates to (i) a transaction notified in accordance with DTR 3.1.2 R, (ii) a disclosure made in accordance with LR 9.8.6R(1) or (iii) a disclosure made in accordance with section 793 of the Companies Act (2006):

DTR 3.1.2 R

3.

Name of person discharging managerial responsibilities/director:

Said Darwazah, Mazen Darwazah and Ali Al-Husry

4.

State whether notification relates to a person connected with a person discharging managerial responsibilities/ director named in 3 and identify the connected person:

Yes: Darhold Limited

5.

Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a non-beneficial interest:

Beneficial interest Darhold Limited

6.

Description of shares (including class), debentures or derivatives or financial instruments relating to shares:

Ordinary Shares

7.

Name of registered shareholders(s) and, if more than one, the number of shares held by each of them:

Citibank N.A.

8.

State the nature of the transaction:

Release of a pledge of 1,838,028 Ordinary Shares

9.

Number of shares, debentures or financial instruments relating to shares acquired:

None

10.

Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage):

N/A

11.

Number of shares, debentures or financial instruments relating to shares disposed:

None

12.

Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage):

N/A

13.

Price per share or value of transaction:

N/A

14.

Date and place of transaction:

London, 19 April 2016

 

15.

Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage):

58,053,028 - 24.25 per cent.

16.

Date issuer informed of transaction:

19 April 2016

 

If a person discharging managerial responsibilities has been granted options by the issuer complete the following boxes

17.

Date of grant

18.

Period during which or date on which exercisable

19.

Total amount paid (if any) for grant of the option

20.

Description of shares or debentures involved (class and number)

21.

Exercise price (if fixed at time of grant) or indication that price is to be fixed at the time of exercise

22.

Total number of shares or debentures over which options held following notification

23.

Any additional information

24.

Name of contact and telephone number for queries

 

Name of authorised official or issuer responsible for making notification

Peter Speirs, Company Secretary, Hikma Pharmaceuticals PLC

Date of notification: 19 April 2016

 

Notes:

This form is intended for use by an issuer to make a RIS notification required by DTR 3.1.4

(1) An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24.

(2) An issuer making a notification in respect of a derivative relating the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24.

(3) An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24.

(4) An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHBBGDSLUBBGLC
Date   Source Headline
17th May 20194:09 pmRNSResult of AGM
17th May 20193:33 pmRNSDirector/PDMR Shareholding
17th May 20197:00 amRNSTrading Statement
2nd May 20197:00 amRNSTotal Voting Rights
1st May 20199:00 amRNSHikma launches 100th injectable medicine in US
15th Apr 20194:26 pmRNSDirector/PDMR Shareholding
15th Apr 201912:23 pmRNSAnnual Financial Report
1st Apr 20195:42 pmRNSTotal Voting Rights
1st Apr 20195:11 pmRNSBlock listing Interim Review
18th Mar 20193:09 pmRNSDirector/PDMR Shareholding
15th Mar 201910:32 amRNSDirector/PDMR Shareholding
14th Mar 20199:14 amRNSDirector/PDMR Shareholding
13th Mar 20191:50 pmRNSDirector/PDMR Shareholding
13th Mar 20191:49 pmRNSDirector/PDMR Shareholding
13th Mar 20197:00 amRNSFinal Results
12th Mar 20197:00 amRNSDirectorate Change
1st Mar 20194:51 pmRNSTotal Voting Rights
28th Feb 20199:00 amRNSHikma establishes partnership with Melinta in MENA
27th Feb 20191:26 pmRNSBlock listing Interim Review
26th Feb 201911:08 amRNSNotice of Results
11th Feb 201910:11 amRNSDirector/PDMR Shareholding
1st Feb 20193:43 pmRNSTotal Voting Rights
29th Jan 20199:00 amRNSHikma launches Mitomycin for Injection
3rd Jan 20199:00 amRNSHikma announces agreement with Sciecure Pharma
19th Dec 20186:30 pmRNSShire
10th Dec 20189:00 amRNSHikma launches Clobazam
3rd Dec 201810:30 amRNSTotal Voting Rights
27th Nov 20189:00 amRNSHikma announces injectable licensing agreement
19th Nov 20189:00 amRNSHikma launches Triazolam Tablets
13th Nov 201811:15 amRNSHolding(s) in Company
8th Nov 20189:44 amRNSHikma announces agreement with Vectura
8th Nov 20187:00 amRNSHikma announces agreement with Vectura
8th Nov 20187:00 amRNSTrading Statement
1st Nov 201812:39 pmRNSTotal Voting Rights
16th Oct 20184:30 pmRNSBlock listing Interim Review
1st Oct 201810:53 amRNSTotal Voting Rights
1st Oct 201810:23 amRNSHolding(s) in Company
3rd Sep 201811:05 amRNSTotal Voting Rights
30th Aug 20189:58 amRNSHolding(s) in Company
28th Aug 201812:45 pmRNSHolding(s) in Company
22nd Aug 20189:41 amRNSDirector/PDMR Shareholding
15th Aug 20187:00 amRNSHalf-year Report
23rd Jul 20189:00 amRNSNotice of Results
9th Jul 20189:00 amRNSHikma enters licensing partnership with Perrigo
2nd Jul 20184:56 pmRNSTotal Voting Rights
15th Jun 20183:24 pmRNSDirector/PDMR Shareholding
8th Jun 201811:50 amRNSDirector/PDMR Shareholding
4th Jun 201810:29 amRNSDirector/PDMR Shareholding
4th Jun 20189:00 amRNSHikma appoints Chief Transformation Officer
1st Jun 201811:34 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.